Joel Beatty
Stock Analyst at Baird
(4.08)
# 389
Out of 4,839 analysts
200
Total ratings
41.25%
Success rate
15.37%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $21.55 | +43.85% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $18.04 | +33.04% | 3 | May 16, 2025 | |
| ELF e.l.f. Beauty | Maintains: Outperform | $85 → $100 | $82.78 | +20.80% | 5 | May 14, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $1.62 | +146.91% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $18.36 | +172.33% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $582.13 | +16.81% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $13.66 | +112.30% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $45.47 | +45.15% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $107.82 | +43.76% | 4 | May 7, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $8 → $7 | $4.95 | +41.41% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $104.35 | +55.25% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $30.05 | +36.44% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $1.94 | +416.80% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $7.07 | +126.31% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $3.92 | +308.16% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $38.34 | +90.40% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $24.11 | +32.73% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $30.22 | +148.18% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $5.35 | +105.61% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.97 | +255.33% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $58.01 | +12.05% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $6.61 | +36.16% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $100.36 | +26.54% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $35.52 | +102.70% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.41 | +4,730.92% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.48 | +204.05% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $10.03 | +149.25% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.37 | +2,337.70% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $10.81 | +159.02% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $7.50 | +113.33% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $1.69 | -26.04% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.34 | +3,183.58% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $15.39 | +276.87% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $18.68 | +28.48% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $12.80 | +40.63% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $2.88 | +108.33% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.20 | +2,483.33% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $4.61 | +507.38% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $289.00 | -39.45% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.24 | +230.19% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $38.79 | +178.42% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $33.26 | +134.52% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.77 | +1,040.25% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $10.99 | +991.90% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.23 | +13,831.89% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $0.80 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.29 | +105.76% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.67 | +17,864.07% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $6.24 | +204.49% | 3 | Nov 10, 2017 |
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $21.55
Upside: +43.85%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $18.04
Upside: +33.04%
e.l.f. Beauty
May 14, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $82.78
Upside: +20.80%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $1.62
Upside: +146.91%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $18.36
Upside: +172.33%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $582.13
Upside: +16.81%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $13.66
Upside: +112.30%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $45.47
Upside: +45.15%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $107.82
Upside: +43.76%
Cogent Biosciences
May 7, 2025
Maintains: Neutral
Price Target: $8 → $7
Current: $4.95
Upside: +41.41%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $104.35
Upside: +55.25%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $30.05
Upside: +36.44%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $1.94
Upside: +416.80%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $7.07
Upside: +126.31%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $3.92
Upside: +308.16%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $38.34
Upside: +90.40%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $24.11
Upside: +32.73%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $30.22
Upside: +148.18%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $5.35
Upside: +105.61%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.97
Upside: +255.33%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $58.01
Upside: +12.05%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $6.61
Upside: +36.16%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $100.36
Upside: +26.54%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $35.52
Upside: +102.70%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.41
Upside: +4,730.92%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.48
Upside: +204.05%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $10.03
Upside: +149.25%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.37
Upside: +2,337.70%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $10.81
Upside: +159.02%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $7.50
Upside: +113.33%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $1.69
Upside: -26.04%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.34
Upside: +3,183.58%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $15.39
Upside: +276.87%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $18.68
Upside: +28.48%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $12.80
Upside: +40.63%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $2.88
Upside: +108.33%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.20
Upside: +2,483.33%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $4.61
Upside: +507.38%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $289.00
Upside: -39.45%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.24
Upside: +230.19%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $38.79
Upside: +178.42%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $33.26
Upside: +134.52%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $8.77
Upside: +1,040.25%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $10.99
Upside: +991.90%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.23
Upside: +13,831.89%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $0.80
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.29
Upside: +105.76%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.67
Upside: +17,864.07%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $6.24
Upside: +204.49%